HRP20040552A2 - Process for the preparation of crystalline imipenem - Google Patents
Process for the preparation of crystalline imipenem Download PDFInfo
- Publication number
- HRP20040552A2 HRP20040552A2 HR20040552A HRP20040552A HRP20040552A2 HR P20040552 A2 HRP20040552 A2 HR P20040552A2 HR 20040552 A HR20040552 A HR 20040552A HR P20040552 A HRP20040552 A HR P20040552A HR P20040552 A2 HRP20040552 A2 HR P20040552A2
- Authority
- HR
- Croatia
- Prior art keywords
- imipenem
- water
- treatment
- solution
- crystalline
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 35
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 title claims description 34
- 229960002182 imipenem Drugs 0.000 title claims description 33
- 238000002360 preparation method Methods 0.000 title claims description 7
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 title 1
- GSOSVVULSKVSLQ-JJVRHELESA-N imipenem hydrate Chemical compound O.C1C(SCCNC=N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 GSOSVVULSKVSLQ-JJVRHELESA-N 0.000 claims description 47
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- 238000002425 crystallisation Methods 0.000 claims description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 239000003245 coal Substances 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229940032007 methylethyl ketone Drugs 0.000 claims 1
- 239000012535 impurity Substances 0.000 description 11
- 238000004108 freeze drying Methods 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 239000003610 charcoal Substances 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 108020004256 Beta-lactamase Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical group C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
- C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
- C07D477/20—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1152DE2001 | 2001-11-16 | ||
| PCT/IB2002/004804 WO2003042215A1 (en) | 2001-11-16 | 2002-11-18 | Process for the preparation of crystalline imipenem |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20040552A2 true HRP20040552A2 (en) | 2004-10-31 |
Family
ID=11097136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20040552A HRP20040552A2 (en) | 2001-11-16 | 2004-06-16 | Process for the preparation of crystalline imipenem |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7332600B2 (pt) |
| EP (1) | EP1448563A1 (pt) |
| JP (1) | JP2005509037A (pt) |
| KR (1) | KR20050044506A (pt) |
| CN (1) | CN1608066A (pt) |
| AR (1) | AR037551A1 (pt) |
| BR (1) | BR0214209A (pt) |
| CA (1) | CA2467427A1 (pt) |
| EA (1) | EA200400682A1 (pt) |
| HR (1) | HRP20040552A2 (pt) |
| HU (1) | HUP0402112A2 (pt) |
| MX (1) | MXPA04004604A (pt) |
| PL (1) | PL368984A1 (pt) |
| WO (1) | WO2003042215A1 (pt) |
| ZA (1) | ZA200403961B (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005514323A (ja) * | 2001-05-18 | 2005-05-19 | ランバクシー ラボラトリーズ リミテッド | 結晶イミペネムの単離方法 |
| JP2005023081A (ja) * | 2003-06-11 | 2005-01-27 | Api Corporation | アルブチン結晶及びその製造方法 |
| US7640048B2 (en) | 2004-07-13 | 2009-12-29 | Dexcom, Inc. | Analyte sensor |
| EP4218548A1 (en) | 2006-03-09 | 2023-08-02 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
| WO2007102842A2 (en) | 2006-03-09 | 2007-09-13 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
| EP2121604A2 (en) * | 2006-12-15 | 2009-11-25 | Schering Corporation | Bisulfite purification of an alpha-keto amide |
| US8621008B2 (en) | 2007-04-26 | 2013-12-31 | Mcafee, Inc. | System, method and computer program product for performing an action based on an aspect of an electronic mail message thread |
| US8199965B1 (en) | 2007-08-17 | 2012-06-12 | Mcafee, Inc. | System, method, and computer program product for preventing image-related data loss |
| US20130276061A1 (en) | 2007-09-05 | 2013-10-17 | Gopi Krishna Chebiyyam | System, method, and computer program product for preventing access to data with respect to a data access attempt associated with a remote data sharing session |
| EP2209787A4 (en) * | 2007-10-08 | 2011-08-03 | Orchid Chemicals & Pharm Ltd | METHOD FOR PRODUCING A CARBAPENEM ANTIBIOTICS |
| US8893285B2 (en) | 2008-03-14 | 2014-11-18 | Mcafee, Inc. | Securing data using integrated host-based data loss agent with encryption detection |
| US9077684B1 (en) | 2008-08-06 | 2015-07-07 | Mcafee, Inc. | System, method, and computer program product for determining whether an electronic mail message is compliant with an etiquette policy |
| CN101891745B (zh) * | 2010-07-20 | 2012-06-13 | 深圳市海滨制药有限公司 | 亚胺培南一水合物晶体的制备方法 |
| CN101891744B (zh) * | 2010-07-20 | 2012-06-13 | 深圳市海滨制药有限公司 | 亚胺培南一水合物结晶的制备方法 |
| WO2012081033A2 (en) * | 2010-12-06 | 2012-06-21 | Sequent Scientific Limited | A process for preparation of imipenem |
| CN103524508B (zh) * | 2013-09-02 | 2016-03-30 | 上海龙翔生物医药开发有限公司 | 一种亚胺培南一水合物的结晶方法 |
| CN113135916A (zh) * | 2020-01-20 | 2021-07-20 | 鲁南制药集团股份有限公司 | 一种亚胺培南制备工艺的除钯方法 |
| CN111747959B (zh) * | 2020-05-15 | 2022-02-11 | 深圳市海滨制药有限公司 | 一种亚胺培南原料药的制备方法 |
| CN114671877B (zh) * | 2022-02-18 | 2023-05-16 | 珠海联邦制药股份有限公司 | 亚胺培南的精制方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE268240C (pt) | ||||
| JPS606957B2 (ja) | 1973-04-10 | 1985-02-21 | ブリストル マイヤ−ズ カンパニ− | 抗生物質誘導体の製造方法 |
| US4194047A (en) * | 1975-11-21 | 1980-03-18 | Merck & Co., Inc. | Substituted N-methylene derivatives of thienamycin |
| DK153486C (da) | 1978-07-03 | 1988-11-28 | Merck & Co Inc | Analogifremgangsmaade til fremstilling af krystallinsk n-formimidoyl-thienamycin-monohydrat |
| US4260543A (en) * | 1978-07-03 | 1981-04-07 | Merck & Co., Inc. | Crystalline N-formimidoyl thienamycin |
| US4292436A (en) * | 1980-06-25 | 1981-09-29 | Merck & Co., Inc. | Process for the preparation of N-protected N-formimidoyl 2-aminoethanethiol |
| US5061730A (en) * | 1987-01-26 | 1991-10-29 | Fujisawa Pharmaceutical Co., Ltd. | Carboxylic acid derivatives |
| DD268240A1 (de) * | 1987-12-05 | 1989-05-24 | Univ Schiller Jena | Verfahren zur erzeugung von fuer die applikation in optiken aus polymeren werkstoffen geeigneten hochreinen 2-hydroxy-4-alkoxybenzophenonen |
| US5321020A (en) * | 1989-03-28 | 1994-06-14 | Pfizer Inc. | Antibacterial 2-carbapenem derivatives |
| CA2023144A1 (en) * | 1989-08-21 | 1991-02-22 | Frank P. Dininno | 2-(quinoliniumalkyl and isoquinoliniumalkyl)-phenyl carbapenem antibacterial agents |
| JPH03256262A (ja) | 1990-03-07 | 1991-11-14 | Nec Corp | 磁気ディスク装置 |
| US5240920A (en) * | 1990-10-11 | 1993-08-31 | Merck & Co., Inc. | 2-(substituted-dibenzofuranyl and dibenzothienyl) carbapenem antibacterial agents |
| JPH06256262A (ja) * | 1993-03-08 | 1994-09-13 | Sekiyu Sangyo Kasseika Center | ２，６−ナフタレンジカルボン酸ジメチルエステルの精製法 |
| US5621084A (en) * | 1994-04-05 | 1997-04-15 | Pfizer Inc. | Process for removal of allyl group or allyloxycarbonyl group |
| DE69605528T2 (de) | 1995-09-08 | 2000-05-04 | Bracco International B.V., Amsterdam | Verfahren zur kristallisierung aus wasser von (s)-n,n'-bis[2-hydroxy-1-(hydroxymethiel)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-1,3-benzoldicarboxamide |
| WO1997033905A1 (en) | 1996-03-14 | 1997-09-18 | Novo Nordisk A/S | Increased yields of a crystallized protein by using a solid adsorption material |
| CN1109688C (zh) | 1999-01-12 | 2003-05-28 | 中国药品生物制品检定所 | 他唑巴坦半水合物的制备与应用 |
| DE60014047T2 (de) | 1999-03-22 | 2006-02-23 | Purac Biochem B.V. | Verfahren zur reinigung von milchsäure auf industrieller basis |
| GB9925215D0 (en) | 1999-10-26 | 1999-12-22 | Cerestar Holding Bv | Process for the manufacture of citric acid |
| CN1192030C (zh) * | 2000-03-31 | 2005-03-09 | 盐野义制药株式会社 | 吡咯烷硫卡培南衍生物的新型结晶 |
| IN191798B (pt) | 2000-11-03 | 2004-01-03 | Ranbaxy Lab Ltd | |
| AR035728A1 (es) * | 2001-01-16 | 2004-07-07 | Merck & Co Inc | Proceso perfeccionado para la sintesis de carbapenem |
| JP2005514323A (ja) | 2001-05-18 | 2005-05-19 | ランバクシー ラボラトリーズ リミテッド | 結晶イミペネムの単離方法 |
| EP1442038A4 (en) * | 2001-09-26 | 2005-01-05 | Merck & Co Inc | CRYSTALLINE FORMS OF CARBAPENEM ANTIBIOTICS AND MANUFACTURING METHOD |
| CN100387599C (zh) * | 2001-09-26 | 2008-05-14 | 麦克公司 | 用于生产碳青霉烯化合物的方法 |
-
2002
- 2002-11-18 MX MXPA04004604A patent/MXPA04004604A/es unknown
- 2002-11-18 HU HU0402112A patent/HUP0402112A2/hu unknown
- 2002-11-18 PL PL02368984A patent/PL368984A1/xx not_active Application Discontinuation
- 2002-11-18 KR KR1020047007508A patent/KR20050044506A/ko not_active Application Discontinuation
- 2002-11-18 JP JP2003544051A patent/JP2005509037A/ja not_active Withdrawn
- 2002-11-18 EA EA200400682A patent/EA200400682A1/ru unknown
- 2002-11-18 EP EP02783385A patent/EP1448563A1/en not_active Withdrawn
- 2002-11-18 CA CA002467427A patent/CA2467427A1/en not_active Abandoned
- 2002-11-18 BR BR0214209-0A patent/BR0214209A/pt not_active IP Right Cessation
- 2002-11-18 US US10/495,681 patent/US7332600B2/en not_active Expired - Fee Related
- 2002-11-18 WO PCT/IB2002/004804 patent/WO2003042215A1/en active Application Filing
- 2002-11-18 CN CNA028260082A patent/CN1608066A/zh active Pending
- 2002-11-19 AR ARP020104429A patent/AR037551A1/es not_active Application Discontinuation
-
2004
- 2004-05-21 ZA ZA200403961A patent/ZA200403961B/en unknown
- 2004-06-16 HR HR20040552A patent/HRP20040552A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005509037A (ja) | 2005-04-07 |
| US20050004359A1 (en) | 2005-01-06 |
| CA2467427A1 (en) | 2003-05-22 |
| WO2003042215A1 (en) | 2003-05-22 |
| CN1608066A (zh) | 2005-04-20 |
| HUP0402112A2 (hu) | 2005-02-28 |
| KR20050044506A (ko) | 2005-05-12 |
| PL368984A1 (en) | 2005-04-04 |
| BR0214209A (pt) | 2004-10-26 |
| US7332600B2 (en) | 2008-02-19 |
| ZA200403961B (en) | 2005-09-19 |
| EP1448563A1 (en) | 2004-08-25 |
| MXPA04004604A (es) | 2004-09-10 |
| AR037551A1 (es) | 2004-11-17 |
| EA200400682A1 (ru) | 2004-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20040552A2 (en) | Process for the preparation of crystalline imipenem | |
| CS215142B2 (en) | Method of making the solid solvates of the syn-+l2-+l-amino-4-thiazolyl+p-2-methoxyimino+p acetymido-3-acetoxymethyl-3-cefem-4-carboxyl acid with cycling ethers | |
| GB2145408A (en) | Improvements in or relating to preparing sodium cefuroxime | |
| CN101891742B (zh) | 美罗培南三水合物结晶的制备方法 | |
| US8293924B2 (en) | Process for the preparation of carbapenem antibiotic | |
| EA006442B1 (ru) | Способ получения кристаллического моногидрата n-формимидоил-тиенамицина (моногидрата имипенема) | |
| CN105859747B (zh) | 一种适于工业化生产的盐酸头孢吡肟的制备方法 | |
| JPH04500819A (ja) | 有機化合物の、または関連する改善 | |
| US7241885B2 (en) | Process for the isolation of crystalline imipenem | |
| Hirata et al. | Precipitation of clavulanic acid from fermentation broth with potassium 2-ethyl hexanoate salt | |
| AU2002347451A1 (en) | Process for the preparation of crystalline imipenem | |
| MX2007010431A (es) | Proceso para purificar tadalafil. | |
| JP2000086690A (ja) | ロキシスロマイシンの精製方法 | |
| CN106565784B (zh) | 头孢洛林酯二钠盐的纯化方法 | |
| CA2575912C (en) | Process for the preparation of optically pure indoline-2-carboxylic acid | |
| CN112480146B (zh) | 一种头孢呋辛酸混合溶剂化物、晶型及制备方法 | |
| CA2124382A1 (en) | 14.alpha.-hydroxy-4-androstene-3,6,17-trione hydrate crystal and process for producing same | |
| AU728627B2 (en) | Cephalosporin crystals and process for their preparation | |
| BG99161A (bg) | Метод и междинен продукт за пречистване на окситетрациклин | |
| WO2004037832A1 (en) | An improved process for the preparation of cefixime | |
| WO2012081033A2 (en) | A process for preparation of imipenem | |
| KR20090090979A (ko) | 결정성 카르바페넴 화합물 및 그의 제조방법 | |
| EP0497125B1 (en) | New process for preparing 2'-(diethylamino)rifamycin P (P/DEA) | |
| KR840000482B1 (ko) | 세팔로 스포린 유도체의 제조방법 | |
| IL29529A (en) | Orally active 7-(4'-(aminoalkyl)phenyl)acetamido cephalosporanic acid derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20051025 Year of fee payment: 4 |
|
| OBST | Application withdrawn |